MK-8776 (SCH 900776)

For research use only. Not for use in humans.

目录号:S2735

MK-8776 (SCH 900776) Chemical Structure

CAS No. 891494-63-6

MK-8776 (SCH 900776)是一种选择性Chk1抑制剂,无细胞试验中IC50为3 nM,比作用于Chk2选择性高500倍。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1921.21 现货
RMB 1733.35 现货
RMB 3015.42 现货
RMB 7966.05 现货
RMB 20229.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的MK-8776 (SCH 900776)发表文献47篇:

产品安全说明书

Chk抑制剂选择性比较

生物活性

产品描述 MK-8776 (SCH 900776)是一种选择性Chk1抑制剂,无细胞试验中IC50为3 nM,比作用于Chk2选择性高500倍。Phase 2。
靶点
Chk1 [1]
(Cell-free assay)
CDK2 [1]
(Cell-free assay)
3 nM 0.16 μM
体外研究

SCH 900776是Chk2和CDK2的低效抑制剂,IC50分别为1.5 μM 和 0.16 μM。SCH 900776对细胞色素P450人肝微粒体亚型1A2,2C9,2C19,2D6,和3A4没有显著的抑制作用。羟基脲下暴露24小时后,SCH 900776诱导DNA复制能力剂量依赖性损失。SCH 900776增强γ-H2AX对羟基脲,5-氟尿嘧啶,和阿糖孢苷的响应。与抗代谢物结合,SCH 900776在2小时内诱导γ-H2AX的累积,表明复制叉瓦解,并且双链DNA断裂。此外,SCH 900776以剂量依赖的方式抑制Chk1 pS296自磷酸化的积累。增殖的WS1细胞暴露于SCH 900776,与Chk1 pS345快速的,剂量依赖性聚集相关,表明正常细胞的循环群诱导Chk1 pS345在暴露于SCH 900776后,是一部分无效循环,这也许通过AT-家族激酶和DNA-PK驱动。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U251 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzUclEzODBxMkCwNEBvVQ>? MWCyOEBp NHvTOWJl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= NWO4TIUxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
HCT115 M{\Dc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\hNlAxNzJyMECgcm0> MlX5NlQhcA>? M3nWfoRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= MlTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
SW620 MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOyNFAwOjByMDDuUS=> NIDUVHMzPCCq MUnk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
IGROV-1 NVm1UmJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e0ZVIxOC9{MECwJI5O NIjm[XAzPCCq M3;jTYRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
HCT116 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLiNlAxNzJyMECgcm0> MonmNlQhcA>? NUHWdoE{\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l NX;oOYVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
MCF10A MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLvNlAxNzJyMECgcm0> MkHONlQhcA>? MUPk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? MknvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
MiaPaCa-2 NVHzcHFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTCNlAxNzJyMECgcm0> NF62Wo4zPCCq MY\k[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
MDA-MB-231 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr0fW8zODBxMkCwNEBvVQ>? MViyOEBp NUe2fpRC\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l M{GySlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W5OVI3Lz5{NEO1PVUzPjxxYU6=
HCC2998 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELNU2gzODBxMkCwNEBvVQ>? M{D0Z|I1KGh? M1\YSYRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= NVn6ZoVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
U87 MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD1TZM6OjByL{KwNFAhdk1? NEHRVVczPCCq M3TrW4Rm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= M1nJPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W5OVI3Lz5{NEO1PVUzPjxxYU6=
MDA-MB-435 M3jjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuyNFAwOjByMDDuUS=> MmTsNlQhcA>? Mkfl[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n Mn3HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
SNB19 MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i2OlIxOC9{MECwJI5O NXzmOZZROjRiaB?= NUPvRplV\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l NIfsXWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1PVUzPid-MkSzOVk2OjZ:L3G+
U20S MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MViyNFAwOjByMDDuUS=> M4H1ZlI1KGh? NG[4dItl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= NH3zXZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1PVUzPid-MkSzOVk2OjZ:L3G+
A498 M3G4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\6e5JUOjByL{KwNFAhdk1? NU\NWWtuOjRiaB?= Mnnp[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n MlPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
TK10 NIHPb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rZ[|IxOC9{MECwJI5O NYLJcYFnOjRiaB?= M{TwN4Rm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= M1O1[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W5OVI3Lz5{NEO1PVUzPjxxYU6=
AsPC-1 MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS3NlAxNzJyMECgcm0> NG[5[XUzPCCq M2OxS4Rm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= NYDWRW9uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
H23 NHq2VYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LROVUxOCCwTR?= NFf5dZMzPCCq NILiSWdFVVOR M2fXZoVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:gVG1Z MoPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUO1OFkoRjJ2MUGzOVQ6RC:jPh?=
H1437 NYflR2YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PM[VUxOCCwTR?= MnfZNlQhcA>? NYr2[JZGTE2VTx?= NEfwSZBmdmijbnPld{B1cGViY3jlcY9{\W6|aYTpfoF1cW:wIITvJHBOYA>? MorhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUO1OFkoRjJ2MUGzOVQ6RC:jPh?=
H1993 M1frdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe2WG42ODBibl2= MWiyOEBp MWDEUXNQ NHzLbWVmdmijbnPld{B1cGViY3jlcY9{\W6|aYTpfoF1cW:wIITvJHBOYA>? M{nMXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUGzOVQ6Lz5{NEGxN|U1QTxxYU6=
H1299 NYe0VVhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPyd2djPTByIH7N Mm\hNlQhcA>? NVnmZ3FoTE2VTx?= NYDMfmdT\W6qYX7j[ZMhfGinIHPo[Y1we2Wwc3n0bZpifGmxbjD0c{BRVVh? NGHsfY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGxN|U1QSd-MkSxNVM2PDl:L3G+
AsPC-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG3SHdKOTBvMUCwNEBvVQ>? NIfWZ4MzPC12OHi= NUe5No9O\W6qYX7j[ZMhfGinIHPo[Y1we2Wwc3n0bZpifGmxbjD0c{Bo\W2laYThZolv\Q>? NVLxeJd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NFQ1OjJpPkKzPFA1PDJ{PD;hQi=>
MiaPaCa-2 MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M162NVExNTFyMECgcm0> MlzFNlQuPDiq MmnD[Y5p[W6lZYOgeIhmKGOqZX3vd4Vve2m2aYrheIlwdiC2bzDn[Y1kcXSjYnnu[S=> M2jqZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEC0OFIzLz5{M{iwOFQzOjxxYU6=
BxPC-3 NE\RSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nLV|ExNTFyMECgcm0> NXrMdIhJOjRvNEjo M{jaXIVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:g[4Vu[2m2YXLpcoU> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhyNESyNkc,OjN6MES0NlI9N2F-
SKOV3 NGX1[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3LNE4{KML3TR?= NXjHR2NHQCCm NGXzPJV{\W6|aYTpfoV{KHSqZTDj[YxtKGyrbnXzJJRwKGenbXPpeIFjcW6nwrC= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV2OEK2PUc,OjN3NEiyOlk9N2F-
OVCAR-8 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm1W4pVOC5|INM1US=> NIfyRpY5KGR? NGS2TIp{\W6|aYTpfoV{KHSqZTDj[YxtKGyrbnXzJJRwKGenbXPpeIFjcW6nwrC= MmLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NEiyOlkoRjJ|NUS4NlY6RC:jPh?=
MV-4-11 M1y0OmFxd3C2b4Ppd{BCe3OjeR?= MXyxNFAuPzByIH7N MnnnOFghcA>? M1W2PYlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV|NkeyNUc,OjN3M{[3NlE9N2F-
U937 MUXBdI9xfG:|aYOgRZN{[Xl? M{TpdlExOC15MECgcm0> MVu0PEBp NYm2SYRncW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> Ml\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{[3NlEoRjJ|NUO2O|IyRC:jPh?=
MOLM-13  M3TGNGFxd3C2b4Ppd{BCe3OjeR?= MYCxNFAuPzByIH7N MmXyOFghcA>? MX7pcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NFXXUWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzOlczOSd-MkO1N|Y4OjF:L3G+
A2058  NGOwd4JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NG[5OZk{Py53LUOwNEBvVQ>? NXfNfGpRPzJiaB?= MXTEUXNQ MWLy[YR2[2W|IITo[UBOUy1zN{e1JGVEPTEEoHL5JFUu\m:uZDD0c{BidiCjdnXyZYdmKG:oIES1JI5O NVTOO2FQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOFg3QDRpPkKzNVQ5Pjh2PD;hQi=>
H2009 MknvR4VtdCCYaXHibYxqfHliQYPzZZk> NGXsZoY2ODBibl2= Mnm2O|IhcA>? MVfEUXNQ M3\pR5Jme3WudIOgbY4hTzFxUz3wbIF{\SCjY3P1cZVt[XSrb36gZ49u[mmwZXSge4l1cCCPSz2xO|c2 NFHuXok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G0PFY5PCd-MkOxOFg3QDR:L3G+
Su.86.86 MUDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWPJV|huPTByIH7N MYm3NkBp M1jEb2ROW09? MlPidoV{fWy2czDpckBIOS:VLYDoZZNmKGGlY4XteYxifGmxbjDjc41jcW6nZDD3bZRpKE2NLUG3O|U> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF2OE[4OEc,OjNzNEi2PFQ9N2F-
HRE MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnfqOVAxKG6P MnHyO|IhcA>? M1zNXGROW09? M3PCWpJme3WudIOgbY4hTzFxUz3wbIF{\SCjY3P1cZVt[XSrb36gZ49u[mmwZXSge4l1cCCPSz2xO|c2 NFiwd4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G0PFY5PCd-MkOxOFg3QDR:L3G+
HMEC M37lNGNmdGxiVnnhZoltcXS7IFHzd4F6 NWK3eHN6PTByIH7N NH\JS2M4OiCq NVi2bI5FTE2VTx?= MUny[ZN2dHS|IHnuJGcyN1NvcHjhd4Uh[WOldX31cIF1cW:wIHPvcYJqdmWmIIfpeIghVUtvMUe3OS=> NWq5VI5IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOFg3QDRpPkKzNVQ5Pjh2PD;hQi=>
U2OS  NVfFd|hsTnWwY4Tpc44hSXO|YYm= NEHofXkzKML3TR?= MWWwMVI1KGh? M1SzTIlv\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGNpczFiYYSgd4VzcW6nIEO0OUBifCCkb4ToJINwdmOnboTyZZRqd26|IHHzJIViemy7IHHzJFIhcCCjZoTldkBi\G2rbnnzeJJifGmxbh?= NYjMVFdYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5N|cyPDdpPkKyPVM4OTR5PD;hQi=>
U2OS  M4jQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm0fHUxNTFyINM1US=> NVjsW5p[OjRxNEigbC=> MXvpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NHTTcWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmzO|E1Pyd-MkK5N|cyPDd:L3G+
U937 MUnGeY5kfGmxbjDBd5NigQ>? MnPRNVAxNTVyMDDuUS=> M2fGclQhcMLi MWfk[YNz\WG|ZYOgeIhmKGO7dHHyZYJqdmVvaX7keYNm\CCFaHuxJIF2fG:yaH;zdIhwenmuYYTpc44h[XRiU3XyNlk3yqCjbnSgdJJmfmWwdIOgR4RkOjWDIHTve45z\We3bHH0bY9v NEHZRmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki2PVg3QSd-MkK4Olk5Pjl:L3G+
U937 NUTDNolmTnWwY4Tpc44hSXO|YYm= MXexNFAhdk1? NID3b241KGkEoB?= MXvy[ZZmenOnczD0bIUh[3m2YYLhZolv\S2rbnT1Z4VlKGmwaHnibZRqd25ib3dCpFNJNXSqeX3p[Ilv\SCrbnPvdpBwemG2aX;uJIlvfG9iRF7B NWrHSGNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4Olk5PjlpPkKyPFY6QDZ7PD;hQi=>
U937 NIHDOY1HfW6ldHnvckBCe3OjeR?= M33VWlExOC13MECgcm0> M3HNdlQhcMLi NEiyeVNqdmS3Y3XzJIlv[3KnYYPl[EBxcG:|cHjvdplt[XSrb36gc4YhUDKDWB?= MnzMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6Nkm4OlkoRjJ{OE[5PFY6RC:jPh?=
HL-60 M2nh[GFxd3C2b4Ppd{BCe3OjeR?= MWOzNE8yODBxM{CwJI5O M1\Ze|I1KGh? MkW5SG1UVw>? NF;YXlRmdmijbnPld{BkgXSjcnHibY5mNWmwZIXj[YQh[XCxcITvd4l{ NWLwW2M1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4Olk5PjlpPkKyPFY6QDZ7PD;hQi=>
ML-1 NV3xRYJGSXCxcITvd4l{KEG|c3H5 M4fN[VI2NzVyL{GwNEBvVQ>? NXXoVIdSOjRiaB?= Ml24SG1UVw>? M3jGNoVvcGGwY3XzJIN6fGG{YXLpcoUucW6mdXPl[EBieG:ydH;zbZM> Mn3IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6Nkm4OlkoRjJ{OE[5PFY6RC:jPh?=
HCT116 NV;tXWtOTnWwY4Tpc44hSXO|YYm= NXjCS3I3OSEEtV2= M1fkXFI1KGh? NYDJWYUx[WK{b3fheIV{KG:oIHPlcIwh[3mlbHWgZZJz\XO2wrC= MnfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3MUC1OlAoRjJ{NUGwOVYxRC:jPh?=
U2OS MkXpSpVv[3Srb36gRZN{[Xl? MlvtNUDDvU1? MVOyOEBp MnL4ZYJzd2ejdHXzJI9nKGOnbHygZ5lkdGViYYLy[ZN1yqB? NFfEfZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWxNFU3OCd-MkK1NVA2PjB:L3G+
Sf9 Mnu3SpVv[3Srb36gZZN{[Xl? NHT6WHZKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzJxQ4njcIlvKEFiZYjwdoV{e2WmIHnuJIlve2WldDDT[lkh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDbN|NRZS2DVGCgbY5kd3Kyb4LheIlwdiCrboTvJIJqd3SrbonsZZRm\CCqaYP0c45mKEhzIHHmeIVzKDFiaIKgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVAhRSByLkG2JO69VS5? NXLMe4R1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPVQ3ODdpPkKxNFk1PjB5PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-chk1(ser345) / CDC25A ; 

PubMed: 27690219     


Western blots for H1299 and A549 cells treated with MK-8776 for various times and assessed for expression of p-chk1 (ser345) and CDC25A.

Cyclin E / pY15-CDK / γH2AX ; 

PubMed: 26595527     


The indicated cell lines were incubated with 2 μM of each drug for 6 h, then lysed and analyzed by western blotting. The top row reflects cells sensitive to MK-8776. The second row reflects cells that are also sensitive to MK-8776, but which fail to degrade cyclin E. The third row reflects MK-8776-resistant cell lines.

27690219 26595527
体内研究 相对于gemcitabine或SCH 900776单独给药,Gemcitabine给药30分钟后,4 mg/kg SCH 900776足以诱导γ-H2AX生物标志物,而8 mg/kg增强肿瘤药效动力学和退化响应。递增剂量的SCH 900776 (16 mg/kg和32 mg/kg)诱导肿瘤响应持续改进。重要的是,在BALB/c 小鼠体内,SCH 900776的剂量与强的生物标志物活化相关,而提高的肿瘤响应与gemcitabine对血液学指标增强的毒性无关。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[1]
- 合并
  • Animal Models: 皮下注射A2780 或 MiaPaCa2细胞的额雌性裸鼠
  • Dosages: ~50 mg/kg
  • Administration: 腹腔内注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 3 mg/mL (7.97 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% propylene glycol
5 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 376.25
化学式

C15H18BrN7

CAS号 891494-63-6
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00779584 Completed Drug: MK-8776|Drug: Gemcitabine Hodgkin Disease|Lymphoma Non-Hodgkin|Neoplasms Merck Sharp & Dohme Corp. October 17 2008 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to know whether your product S2735 is the optically pure R enantiomer or whether it is a racemic mix.

  • 回答:

    Our S2735 MK-8776 (SCH 900776) is R enantiomer.

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

相关Chk产品

Tags: 购买MK-8776 (SCH 900776) | MK-8776 (SCH 900776)供应商 | 采购MK-8776 (SCH 900776) | MK-8776 (SCH 900776)价格 | MK-8776 (SCH 900776)生产 | 订购MK-8776 (SCH 900776) | MK-8776 (SCH 900776)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID